Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Mark Grayson

Mark Grayson Mark Grayson is a former deputy vice president of public affairs at PhRMA focusing on intellectual property, trade and international issues.

Recent Posts

Pharmaceutical industry increases investment in neglected tropical diseases by 28%

By Mark Grayson  |    December 8, 2015
Medical research and development (R&D) is a difficult concept for many to translate into a tangible outcome. Yet the future of medical innovation and the new medicines it spawns is very much...   Read More

Strengthening IP would significantly boost India’s economy

By Mark Grayson  |    November 2, 2015
On the heels of the October 28 U.S.-India Trade Policy Forum, PhRMA Chairman and Merck Chief Executive Officer Ken Frazier traveled to New Delhi this week for meetings with top Indian government...   Read More

5 Reasons why biopharmaceutical patents are different

By Mark Grayson  |    September 10, 2015
Intellectual property protection has deep, historical roots in the United States.  Article I, Section 8 of the U.S. Constitution expressly recognizes the role of patents to “promote the Progress of...   Read More

Free Trade Agreements May Be Good For Your Health

By Mark Grayson  |    August 27, 2015
A new report by the Geneva Network titled “Trading for Health: Quantifying the Impact of Free Trade Agreements on Health Outcomes” recently called into question many claims being made by groups...   Read More

Medicine Spending Relatively Stable Following Increased Regulatory Data Protection in Canada and Japan

By Mark Grayson  |    July 16, 2015
There has been much discussion about the effects of adding 12 years of data protection for biologics in the TPP.  However, fears that this could add to the cost of healthcare seem to be unfounded. A ...   Read More

India’s IP Policies: Still Much Room for Improvement

By Mark Grayson  |    May 6, 2015
PhRMA Associate Vice President Amiee Aloi testified on May 5 before a U.S. International Trade Commission hearing examining the progress India is making to address relevant industrial trade and...   Read More

World IP Day: The Foundation of Modern Life in America

By Mark Grayson  |    April 30, 2015
This week marks the celebration of  World Intellectual Property Day – an opportunity to reflect on and highlight the many ways that patents and trademarks serve as the very foundation of modern life...   Read More

Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending

By Mark Grayson  |    March 23, 2015
The biopharmaceutical industry comes out on top as the country’s manufacturing leader in innovation and economic contributions in a new report from ndp | analytics. According to the analysis, the...   Read More

Patient Safety Demands that Drug Compounders Comply With Law

By Mark Grayson  |    December 11, 2014
“When compounded products are not made according to strict quality standards appropriate for their scale of production, the results can be deadly.”  Six public health organizations wrote this to FDA...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates